Select Page
L'Actuel Journal Club

For 30 years, the Clinique médicale l’Actuel, under the medical direction of Dr. Réjean Thomas, has been bringing together healthcare professionals, with a focus in virology, to learn from guest experts and discuss the most relevant clinical practice challenges facing them today.

POST World AIDS 2016

With Dr. Réjean Thomas and Dr. Jean-Pierre Routy


After clicking PLAY, click on the lower bar’s subtitles icon [CC] for english subtitles.


  • PrEP: an essential tool to reduce the number of people infected with HIV.
  • Dual therapy: pharmaceutical companies are seriously interested and are financing studies.
  • Immune therapies for HIV treatment: can we learn from what is being done in oncology?  
  • HIV vaccine: effectiveness is reported to be 68%, not 38%.

This activity is supported
by an educational grant from:
ViiV Healthcare



AIDS 2016 — 21st International AIDS Conference

After returning from Durban, where the 21st International AIDS Conference was held, Dr. Jean-Pierre Routy and Dr. Réjean Thomas provide an overview of the main topics that were discussed there.

The goals set for South Africa at the first Conference in Durban (AIDS 2000), the first to be held on the African continent, have largely been achieved and even surpassed: the number of people on antiretrovirals has gone from 10,000 to 12 million, reducing the mortality rate by about 45%.

New immune therapies, increasingly used in oncology, are an inspiration for research on HIV treatment. Dual therapy, which has until now been mostly conducted in isolation and independently, has finally attracted interest from pharmaceutical companies, which are beginning to fund studies in this area.

PrEP (pre-exposure prophylaxis), a headline topic at the Conference, is undoubtedly a crucial tool to reduce new HIV infections, but availability remains limited, except in certain places.

Good news for the future: following reanalysis of a study carried out in Thailand, which had indicated that the efficacy of the HIV vaccine was only 38%, revealed that it was actually 68%. 

Réjean Thomas, MD, Dhc

Réjean Thomas, MD, Dhc


CEO – Founder
Clinique médicale l’Actuel: Centre of Excellence HIV–STI–Hepatitis
Affiliated with the Centre hospitalier de l’Université de Montréal (CHUM)
Québec, Canada

Jean-Pierre Routy, M.D. FRCPC

Jean-Pierre Routy, M.D. FRCPC


Division of Hematology and Chronic Viral Illness Service
McGill University Health Centre
Incumbent – Louis Lowenstein Chair in Hematology & Oncology
Professor of Medicine
McGill University, Montréal, Québec



You must be logged in to view the complete program

ViroChannel has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced.

Réjean Thomas, MD, Dhc has a financial interest/relationship or affiliation with:
Advisory Boards: AbbVie, Bristol-Myers Squibb Janssen, Gilead, Merck, ViiV Healthcare

Jean-Pierre Routy, MD, FRCPC has a financial interest/relationship or affiliation with: 

Disclosure of Unlabeled Use The faculty of this educational activity may include discussions of products that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. No endorsement of unapproved products or uses is made or implied by coverage of these products or uses. No responsibility is taken for errors or omissions. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.